Quick Answer
Apogee Therapeutics, Inc. reported Operating Income Loss of -$285.60 million for the year ending 2025.
- Apogee Therapeutics, Inc. showed a decrease of -31.7% in Operating Income Loss from 2024 to 2025.
- This data is from Apogee Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$1.82 million | Q3 2022: -$10.51 million | Q1 2023: -$12.66 million | Q2 2023: -$18.89 million | Q3 2023: -$24.31 million | Q1 2024: -$38.18 million | Q2 2024: -$44.12 million | Q3 2024: -$58.69 million | Q1 2025: -$63.10 million | Q2 2025: -$73.17 million | Q3 2025: -$71.28 million.
- Over the full 4 years of available data (2022 to 2025), Apogee Therapeutics, Inc.'s Operating Income Loss has declined by 829.5%.
- Historical annual values: Fiscal year 2025: -$285.60 million | Fiscal year 2024: -$216.87 million | Fiscal year 2023: -$93.00 million | Fiscal year 2022: -$30.73 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: